Features of PGT’S Intellectual Property


  • Early priority dates for many patent families: Much of PGT’s innovation is based upon ideas from Nobel Laureate Sydney Brenner, a visionary pioneer of molecular biology.
  • An understanding of current and future limitations of next generation sequencing: This led PGT to develop novel approaches and inventions to address these limitations.
  • Broadly applicable technologies: PGT approaches augment next generation sequencing and meet the needs of a broad range of end applications using the wide range of commonly used NGS platforms.
  • Broad interlocking patent claims: In many instances claims cover multiple facets of a fundamental approach and/or application with broad issued claims.
  • Business development strategy: The focus is aimed at selling and assigning PGT inventions, rather than keeping our innovations in-house.

Beneficiaries


  • Next Generation Sequence (NGS) Platform Providers who develop the machines that enable massively parallel sequencing of clonally amplified or single DNA molecules.
  • Reagent and device providers to augment NGS platforms who develop reagents and machines used to add or improve features of broadly adopted sequencing platforms.
  • NGS service providers who use combinations of sequencing platforms and auxiliary devices and reagents to generate masses of sequencing data for any application.
  • Molecular diagnostic companies whose core objectives include the determination of disease predisposition, presence of disease and selection of treatment options.
  • Early stage companies who are providing reagents, devices and/or services and are looking for ways to strengthen their competitive advantage.